KMT2D is an epigenetic modifier that enhances the expression of Kruppel-like factor-4 (KLF4) and leukemia inhibitory factor receptor (LIFR), which are involved in the activation of the PI3K/Akt and EMT pathways and promote the outgrowth and metastasis of PCa. The gene discussed is AKT1; the disease is posterior cortical atrophy.